Facebook Twitter Youtube Vk Rss
Facebook Twitter Youtube Vk Rss
  Trending
Dermata Therapeutics Volume Alert March 24, 2023
DiamondHead Holdings hits New 52-week High Following Yesterday’s PIPE Investment News March 23, 2023
ZyVersa Therapeutics Higher in Premarket Trading March 23, 2023
T2 Biosystems Plans to Add Candida Auris Detection to T2Candida Panel March 23, 2023
SQZ Biotechnologies Confirms Complete Response in Clinical Trial March 23, 2023
Next
Prev

24/7 Market News – (NASDAQ:RGLS) REGULUS THERAPEUTICS INC. Just announced the FDA orphan drug designation from the FDA.

REGULUS THERAPEUTICS INC
  • Jun 21, 2022 at 7:49 AM

Shares are up slightly in pre-market on light trading. currently .30 on only 498 trades.

Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease

https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-receipt-of-fda-orphan-drug-designation-for-rgls8429-for-the-treatment-of-autosomal-dominant-polycystic-kidney-disease-adpkd-301571856.html

RelatedNews

Page 1 of 2
12

Want more news like this? Check out our homepage!

Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Recent News

Follow Us

Facebook-f Twitter Youtube

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

24/7 MarketNews is a leading market news platform for public companies. As a pioneer in digital media, we are dedicated to the swift distribution of financial market news and information. We take great pride in creating innovative public relations campaigns that help our clients reach their target audience.

Search by keyword

© 2022-2023 24/7MarketNews – The Experts in Investor and Public Relations

Add New Playlist

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.